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INTRODUCTION
Salvage therapies for relapsed or refractory aggressive
non-Hodgkin’s lymphomas (NHLs) commonly include
platinum and etoposide. Two common drug regimens are
DHAP [dexamethasone, cytosine arabinoside (Ara-C),
and cisplatin] and ESHAP (etoposide, methylprednisone,
Ara-C, and cisplatin). The EPIC regimen (etoposide,
prednisolone, ifosfamide, and cisplatin) has been shown
to be an effective low-toxicity regimen for relapsing
lymphoma [1]. However, these salvage protocols are
limited by poor responsiveness and toxicity [2]. Currently,
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Background/Aims: To date, an effective salvage chemotherapy regimen for the treatment of refractory or
relapsing non-Hodgkin’s lymphoma (NHL) has not been discovered. This study was conducted to evaluate the
efficacy and safety of gemcitabine, etoposide, cisplatin, and dexamethasone in relapsed or refractory NHL patients. 
Methods: All patients had histologically proven relapsed or refractory NHL. Treatments consisted of gemcitabine
700 mg/m
2 by continuous i.v. on days 1 and 8; etoposide 40 mg/m
2 by i.v. on days 1-4; cisplatin 60 mg/m
2 by i.v.
on day 1; or dexamethasone 40 mg by i.v. on days 1-4 (GEPD) every 21 days. The primary end point was the
patient response rate following two cycles of treatment. After two cycles, stem cells were harvested using
mobilizing regimens (ESHAP or GEPD plus filgrastim), and this was followed by autologous stem cell
transplantation or four additional cycles of GEPD.
Results: Between January 2005 and January 2006, 20 patients (13 males and 7 females) were enrolled in the
study. The median age was 53 (range 16-75) years. The most common histology was diffuse large B-cell
lymphoma (n=10). The median follow-up duration was 5.2 (range 1.0-16.0) months. After two cycles, the overall
response rate was 50.0% (10/20), including two complete responses and eight partial responses. The dose-
limiting toxicity was myelosuppression. Grade IV neutropenia and thrombocytopenia occurred in 13 (65.0%) and
6 patients (30.0%), respectively. The median number of CD34-positive cells collected was 6.0 (range, 2.8-11.6)
×10
6/kg. Of the 17 patients < 66 years of age, 4 (23.5%) proceeded to autologous stem cell transplantation.
Conclusions: GEPD chemotherapy in patients with refractory or relapsed NHL was effective as a salvage therapy
and helpful for stem cell harvest followed by autologous transplantation. (Korean J Intern Med 2009;24:37-42)
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tory NHL. Even though NHLs are commonly chemosen-
sitive, 50-60% of patients experience primary treatment
failure or relapse after an initial response.
Gemcitabine has a chemical structure that is similar to
cytarabine. However, its pharmacological characteristics
and mechanisms of action differ. Gemcitabine has been
tested in a number of phase II studies as a single agent for
the treatment of NHL. In these studies, moderate activity
was noted in heavily pretreated lymphoma patients, while
drug-related toxicities with the single-agent gemcitabine
were mild [3-8]. In a phase II study of gemcitabine, cis-
platin, and methylprednisolone (GEM-P) in poor prog-
nostic primary progressive or multiply relapsed Hodgkin’s
and non-Hodgkin’s lymphoma, the overall objective
response rate was 80% in 20 patinets [9].
The aim of this study was to evaluate the overall response,
disease-free survival, overall survival, and efficacy of stem
cell mobilization on gemcitabine, etoposide, cisplatin, and
dexamethasone (GEPD) in relapsed or refractory non-
Hodgkin’s lymphoma.
METHODS
Eligibility criteria
All patients evaluated for NHL had refractory or
relapsed disease after previous chemotherapy. The
eligibility criteria for patients in this study included: (1)
men or women aged between 16-75 yr; (2) a histologically
proven diagnosis of NHL (previous diagnoses were
reformulated according to the WHO classification of
lymphoid neoplasms)[10]; (3) documentation of refrac-
tory or relapsing disease after one or more chemotherapy
treatment regimens; (4) an Eastern Cooperative Oncology
Group Scale performance status less than 2; (5) at least
one site of disease measurable in two dimensions using
clinical examination, CT scan, or MRI scans; (6) no pre-
vious therapy with gemcitabine, high-dose chemotherapy,
or stem cell transplantation; (7) a glomerular filtration
rate of >60 mL/min, normal hepatic function, and normal
bone marrow function. The patients were graded accord-
ing to the Ann Arbor classification and international
prognostic index (IPI). We excluded patients with acquired
immunodeficiency syndrome (AIDS)-related lymphoma
and those testing positive for human immunodeficiency
virus. The study was conducted in accordance with the
Declaration of Helsinki and was consistent with the
International Conference in Harmonization Good Clinical
Practice (ICH GCP) and applicable regulatory requirements.
A recognized ethics committee reviewed and approved the
study protocol.
Disease evaluation
The initial evaluation before commencement of
chemotherapy included: medical history and physical
examination; laboratory analyses including a complete
blood count; renal and liver function and serum lactate
dehydrogenase (LDH); glomerular filtration rate assess-
ment by EDTA51Cr clearance; CT scans of the chest,
abdomen and pelvis; and bone marrow biopsies for all
NHL patients. All assessments were performed within 7
days of the first treatment, except the CT scans and bone
marrow biopsies, which were performed within 28 days.
Study treatment 
The GEPD regimen consisted of gemcitabine (700
mg/m
2) and was delivered as a continuous intravenous
infusion over 70 min on days 1 and 8. Etoposide (40
mg/m
2) was delivered as an intravenous infusion over 30
min on days 1-4. Cisplatin (60 mg/m
2) was given over 1
hour on day 1. Pre- and post-chemotherapy hydration was
given on the day of cisplatin administration. Patients also
received dexamethasone (40 mg) intravenously on days 1-4.
The cycle was repeated every 21 days. Patients were given
allopurinol 300 mg once a day for the first cycle. Throughout
their treatment, cotrimoxazole (480 mg) was given twice a
day three times a week to all patients for prophylaxis
against pneumocystis carinii pneumonia. The institutional
standard antiemetic regimen including metoclopromide,
any anti-serotonin anti-emetic agent, and dexamethasone
was provided prior to chemotherapy. Chemotherapy was
delayed on day 8 until recovery for a maximum of 3 weeks
if the neutrophil count was <0.5×10
9/L and/or the platelet
count was <50×10
9/L or if the patient demonstrated grade
3/4 non-hematological toxicity (except for nausea,
vomiting, and alopecia). If, on day 21, the neutrophil count
was <1.0×10
9/L and/or the platelet count was <75×10
9/L
chemotherapy treatment was delayed. The dose of
cisplatin was reduced by 50% in the event of grade 2
neurological toxicity or grade 1 renal toxicity. In the event
of febrile neutropenia, grade 4 thrombocytopenia, or ≥
grade 3 non-hematological toxicity (except alopecia),
treatment with 75% of the dose for the three drugs (except for
dexamethasone) was given and was returned to the full dose
if the reduced dose was well-tolerated (absence of toxicity).
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The response to salvage therapy was assessed after a
minimum of two courses of chemotherapy. International
Workshop NHL response criteria were used to assess the
response to treatment [11]. In addition, the toxicity was
evaluated and graded according to the National Cancer
Institute Common Toxicity Criteria (NCI CTC) version 3.0
grading system. 
Statistical analysis 
This study was designed as a prospective, non-random-
ized, open-labeled, multicenter, phase II study. The
primary end points of the study were overall response
(CR+CRu+PR) and toxicity. The secondary end points
were efficacy of stem cell mobilization, progression-free
survival, and overall survival. The patient characteristics,
responses, toxicities, and efficacy of stem cell mobilization
were evaluated by descriptive methods. The progression-
free survival and overall survival were calculated using the
Kaplan-Meier method. Statistical analysis was performed
using SPSS 13.0 for Windows. All p values<0.05 were
considered to be significant. In addition, the current trial
used a two-stage optimal design, as proposed by Simon,
with an 80% power to accept the hypothesis and 5%
significance to reject the hypothesis. The duration of a
complete remission was measured from the date of
achieving the complete remission to the date of relapse for
patients who relapsed, or the date of the last contact for
patients who had not relapsed. The disease-free survival
was estimated from the start date of chemotherapy to the
date of relapse for patients who relapsed, or the date of
last contact for patients who had not relapsed. Patients
who died in remission were included as treatment failures
and were not excluded from the analysis. Overall survival
was estimated from the start date of chemotherapy to the
date of death for patients who died.
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Table 2. Response to GEPD chemotherapy with relapsed or refractory Non-Hodgkin’s lymphoma
Response (%)
CR PR SD PD
Whole study 2 (10.0) 8 (40.0) 3 (15.0) 5 (25.0)
Histologic type
B-cell 1 (7.7) 7 (53.8) 2 (15.4) 3 (23.1)
T-cell 1 (14.3) 1 (14.3) 1 (14.3) 2 (28.6)
Pre-treatment status
Relapsed 1 (11.1) 5 (55.6) 1 (11.1) 1 (11.1)
Primary refractory 1 (9.1) 3 (27.3) 2 (18.2) 4 (36.4)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
Table 1. Patients’ characteristics
Characteristics Number of patients
Age (years)
Median (range) 53 (16-75)
Gender
Male 15
Female 5
WHO performance status
11 4
26
International prognostic index
Low 4
Low-intermediate 6
High-intermediate 8
High 2
Histologic subtype
Diffuse large B cell 10
Mediastinal large B cell 1
PTCL-unspecified 6
Extranodal NK/T cell 1
Anaplastic large B cell 1
T-cell rich B cell 1
Stage
I2
II 3
III 6
IV 9
Disease status
Primary refractory 11
Relapsed 9
Lactate dehydrogenase
≤ULN 14
≥ULN 6
Regimen of previous chemotherapy
R-CHOP 7
CHOP 6
COBLAM 1
CHEP 2
A-CHOP 1
ESHAP 1
DHAP 2
Median disease free interval (range) 5.2 months 
(1.0-16.0)
PTCL, peripheral T cell lymphoma; ULN, upper limit of normal rangeRESULTS
Patients’ Characteristics
Twenty patients were enrolled between January 2005
and January 2006 from three medical centers in Korea.
The patients’ characteristics are summarized in Table 1.
Among these patients, WHO performance status I and II
were noted in 14 and 6 patients, respectively. The
histological type was diffuse large B cell in 10 patients,
PTCL (peripheral T cell lymphoma) in 6 patients, and
mediastinal large B cell, extranodal NK/T cell, anaplastic
large B cell, and T-cell rich B cell in the remaining
patients. Before the first GEPD cycle, the disease status
was primary refractory in 11 patients, and relapses had
occurred in 9 patients. Patients with stage I, II, III, and
IV disease included 2, 3, 6, and 9 patients, respectively.
Previous treatment regimens were R-CHOP in 7 patients,
CHOP in 6 patients, CHEP in 2 patients, DHAP in 2 patients,
A-CHOP in 1 patient, COBLAM in 1 patient, and ESHAP
in 1 patient. The median disease-free interval was 5.2
months.
Response to treatment
The objective response rate (RR) for all evaluated
patients was 50.0% (95% CI:28.1-71.9%). Two CRs (10.0%)
and 8 PRs (40.0%) were noted. The response was not
evaluated for 2 patients who died early due to progression
of disease. However, they are included in the analysis of
response rate for intent-to-treat analysis. The responses
are summarized in Table 2. Each of the response rates
were divided into pretreatment status and histological
type. The response rate of B-cell type lymphoma was better
than that of T-cell type lymphoma. The response rates of
B-cell type and T-cell type lymphomas were 61.5% (95%
CI:23.5-76.5%) and 28.6% (95% CI:11.0-68.2%), respec-
tively. The response rates of the relapsed patients and the
primary refractory patients were 66.7% (95% CI:34.0-
99.4%) and 36.4% (95% CI:6.6-68.2%), respectively. One
of the relapsed patients and one of the primary refractory
patients were not evaluated for response, due to early death.
Autologous SCT as a consolidation therapy was performed
in 7 patients. The mobilization regimen was GEPD or
ESHAP. The CD34 positive cell yields were adequate
(median: 6.03×10
6/kg, Table 3). No transplant-related
mortality occurred. The median follow-up duration was
5.2 months (range, 1.0-16.0 months). The median survival
time and the median time to progression were not
reached due to short follow-up duration (data not shown).
Toxicity
Toxicity was recorded in all 20 patients. The most
important toxicity was myelosuppression. NCI-CTC grade
IV neutropenia was observed in 13 patients (65%, Table 4).
DISCUSSION
NHLs are responsive to current chemotherapy treat-
ment regimens; however, the outcome of patients who do
not achieve a response to initial treatment is poor. To date,
there is no available salvage chemotherapy that is effective
for primary refractory or relapsing NHL.
Gemcitabine is a novel nucleoside analogue with proven
activity in solid tumors, and was used for NHLs in the late
1990s. It acts as a competitive substrate with deoxy-
cytidine for incorporation into DNA, thus inhibiting DNA
replication and repair. Despite its structural similarity to
Ara-C, gemcitabine’s cellular pharmacology and mech-
anism of action differs markedly [13]. Laboratory evidence
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Table 3. Mobilization regimens and CD34-positive cell counts
Number of patients
Mobilization regimens
GEPD 3
ESHAP 4
Median number of CD34 positive cells 6.0
collected (×10
6/kg) (range : 2.8-11.6)
Table 4.  Adverse reactions of GEPD chemotherapy
Grade I (%) Grade II (%) Grade III (%) Grade IV (%)
Anemia 5 30 20 10
Neutropenia 5 5 0 65
Thrombocytopenia 5 5 25 30
Febrile neutropenia 10 0 15 0
Stomatitis 0 10 10 5
Alopecia 20 5 0 0suggests that a prolonged infusion rate of 10 mg/m
2 per
min may be more effective. In fact, maximal intracellular
levels of difluorodeoxycitidine triphosphate, which is the
principle active metabolite of gemcitabine, are generated
at sustained plasma gemcitabine concentrations of 15-20
µmol/L.
In a phase II study of gemcitabine, cisplatin, and meth-
lyprednisolone (GEM-P) in poor prognostic primary pro-
gressive or multiply relapsed Hodgkin’s and non-
Hodgkin’s lymphoma involving 20 patients, the overall
objective response rate was 80% (including 25% CR). No
case of febrile neutropenia or hemorrhage with throm-
bocytopenia was encountered [9]. The overall response
rate of chemotherapy with ifosfamide, carboplatin, and
etoposide (ICE) in primary refractory or relapsed NHLs
was 65%. Only 58% of the 163 patients in that study pro-
ceeded to transplantation, and the event-free survival for
the entire cohort was 25% at 40 months. The response rate
to gemcitabine as a single agent in the treatment for
relapsed or refractory NHLs was 20% [4]. In a phase II
study conducted by the National Cancer Institute of
Canada, the clinical trial group that was treated with gem-
citabine, dexamethasone, and cisplatin (GDP) had a
response rate of 49% [15]. The response rate with GEPD
chemotherapy was similar to that of other regimens. 
Hematological toxicity of salvage regimens used before
SCT is often substantial and may interfere with sub-
sequent attempts at stem cell mobilization. For example,
in the initial report on DHAP chemotherapy, 43 of 90
patients (48%) required hospitalization for the man-
agement of febrile neutropenia or documented infection,
and 10 of 90 patients (11%) died [14]. In our study, 7
patients proceeded to autologous stem cell collection. The
mobilization regimens were GEPD chemotherapy (n=3)
and ESHAP chemotherapy (n=4). The median number of
harvested CD 34-positive cells was 6.03×10
6/kg. This
result was not different from results reported with ICE
and DHAP chemotherapy.
The principal toxicity of GEPD was myelosuppression,
which was well tolerated. The non-hematological toxicity
was mild with no observed grade III-IV toxicity. No
transplant-related mortality occurred. The main toxicity of
GEM-P and GDP chemotherapy was myelosuppression
[9]. Therefore, the toxicity associated with GEPD
chemotherapy was the same as GEM-P and GDP
chemotherapy and lower than ESHP chemotherapy. The
median overall survival and relapse-free survival was 6.9
and 6.3 months, respectively, which is consistent with
prior studies [4,6].
In conclusion, GEPD chemotherapy is an effective
regimen for patients with primary refractory or relapsed
NHL and does not interfere with the ability to harvest
autologous stem cells for subsequent transplantation. The
associated toxicity was myelosuppression, and this was
the principal toxicity and cause of treatment-related
mortality. The median overall survival and relapse-free
survival were 6.9 months and 6.3 months, respectively.
Longer follow-up intervals are needed to determine the
overall survival and relapse-free survival in our study.
Additional studies are planned to compare GEPD with
DHAP or ESHAP in randomized phase III trials as a
second-line therapy before ASCT. 
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